MRD in Ph+ ALL: How Do You Measure It and What Does It Mean?
September 6th 2023Although it is well-established that MRD negativity plays an important prognostic role in Ph-positive ALL, the optimal method to assess MRD in this disease and how to use this information therapeutically are still being established.
Read More
Key Data From the BMT CTN 1506/MORPHO Trial of Gilteritinib in FLT3-ITD+ AML
June 15th 2023Mark J. Levis, MD, PhD, discusses the takeaways from the phase 3 BMT CTN 1506/MORPHO trial which evaluated maintenance gilteritinib after allogeneic stem cell transplant in patients with FLT3-ITD–positive acute myeloid leukemia.
Watch
Teclistamab With Talquetamab Shows a Manageable Safety Profile in RRMM
June 12th 2023Yael Cohen, MD, discusses the main safety findings from the phase 1/2 RedirecTT-1 trial, which is evaluating the combination of teclistamab-cqyv and talquetamab for the treatment of patients with relapsed/refractory multiple myeloma.
Watch
Gilteritinib as Maintenance Shows Benefit in MRD+ FLT3-Mutant AML Post HCT
June 12th 2023In patients with FLT3-ITD–mutant acute myeloid leukemia and detectable minimal residual disease after hematopoietic stem cell transplant, treatment with gilteritinib elicited a 48% reduction vs patients without detectable MRD.
Read More
Watch and Wait Remains the Standard in Inactive Early-Stage CLL
June 11th 2023A watch-and-wait approach should remain the standard of care, even in the era of targeted therapies, in patients with early-stage chronic lymphocytic leukemia with inactive disease, according to data from the 2023 EHA Congress.
Read More
Investigational BET Inhibitor Achieves Potent Spleen Volume Reduction in Myelofibrosis
June 10th 2023With BMS-986158 plus ruxolitinib or fedratinib treatment in patients with myelofibrosis, reduction in splenic volume was reported among all patients in part 1A and became more robust at week 24.
Read More
Phase 3 PhALLCON Trial of Ponatinib and Reduced-Intensity Chemo Shows Promise in Ph+ ALL
June 9th 2023Findings from the phase 3 PhALLCON trial show that ponatinib plus reduced-intensity chemotherapy could be a new standard of care for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.
Read More
Pelabresib Leads to Hematologic Response in Hydroxyurea-Refractory or Intolerant High-Risk ET
June 9th 2023Preliminary findings from arm 4 of the phase 2 MANIFEST trial show hematologic response and symptom improvement with pelabresib in high-risk essential thrombocythemia that is refractory or intolerant to hydroxyurea.
Read More
Teclistamab Follow-Up Data Yields Consistent Results in Relapsed/Refractory Multiple Myeloma
June 9th 2023At 2-year follow-up, patients with relapsed/refractory multiple myeloma treated with teclistamab achieved a median progression-free survival of 12.5 months with a median duration of response of 24 months.
Read More
Rapid Responses Seen With Daratumumab Combo in RRMM Pretreated With Lenalidomide
June 9th 2023In patients with relapsed/refractory multiple myeloma who were previously treated with lenalidomide, the combination of daratumumab, ixazomib, and dexamethasone led to improved overall response rates.
Read More